Trials in UK found dexamethasone to be useful against COVID-19. World Health Organization (WHO) welcomed the results saying that it can be lifesaving for people who are in critical situation with COVID-19.
UK did first successful trial for dexamethasone. It is an inexpensive medicine which successfully treated coronavirus patients.
Many COVID-19 patients recover immediately and don’t need to go to the hospitals. However, some people who have weak immune systems have to go to doctors for treatment and have lower chances for survival.
COVID-19 infects the lungs of the patients. As coronavirus damages lungs, patients feel difficulty in breathing and need to use ventilators or oxygen masks.
Lung problems occur due to inflammation. Dexamethasone is useful as it reduces inflammation during illnesses, especially arthritis and asthma.
WHO gave positive statement about the drug and declares it beneficial for severe coronavirus cases. WHO was working on different drugs for treatment of COVID-19.
Trials are ongoing for various medications to notice their benefits against the COVID-19. Hydroxychloroquine was the most discussed drug because of President Trump’s statement. It became a political issue more than a treatment of the virus.
There was another drug, remdesivir, which figured out to be useful for COVID-19 treatment. The antiviral drug is useful but it is very expensive.
Dexamethasone was being used in UK since 1960. Like other drugs, this also wasn’t really for the virus. However, it is a breakthrough.
WHO says that it is useful only for those who are seriously ill. It does not work for people who are in stable condition.
Dr Tedros Adhanom Ghebreyesus, WHO Director-General congratulated the government of UK, other organizations and institution which partook in the research.
“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” he said.
The drug is in the WHO Model List of Essential Medicines since 1977 in multiple formulations. There is another advantage for the drug over others that it s very inexpensive and is “affordably available in most countries.”
Fadela Chaib, Communications Officer and Spokesperson of WHO, said that the researchers had given the data to WHO. She also said that WHO will execute a large scale research and it will be analyzed that what is the perfect time to use it during illness and when should be avoided.